Superiority of Low-Dose Benzbromarone Add-On to Low-Dose Febuxostat Compared With Febuxostat Monotherapy in Gout With Combined-Type Hyperuricemia.

Xiaomei XueMingshu SunZhen Liu Nicola Dalbeth Yuwei HeXinde LiHan QiYing ChenXuan YuanMaichao LiAichang JiRobert Terkeltaub Changgui Li

Published in: Arthritis care & research (2024)

Simply adding on low-dose benzbromarone (25 mg/day) to low-dose (20 mg/day) febuxostat showed superior urate lowering compared to febuxostat monotherapy in gout with a combined-type hyperuricemia. For selected patients, expedited achievement of the SU target in more than 75% of patients using one titration step and low xanthine oxidase inhibitor and uricosuric doses is a potential alternative to standard ULT regimens.

Keyphrases

low dose
uric acid
end stage renal disease
high dose
newly diagnosed
ejection fraction
peritoneal dialysis
randomized controlled trial
metabolic syndrome
open label
climate change
clinical trial